INTRODUCTION
In man idiotypic determinants common to monoclonal immunoglobulin (Ig) from different individuals have been observed in two different circumstances. First, cross-idiotypic determinants have been demonstrated among monoclonal Ig that had an identical antibody activity (1, 2) , and second, common idiotypes have been found, although rarely, on monoclonal Ig purified from the serum of different individuals within a family (3) . The former idiotypic determinants have been shown conclusively to be related to the structure of the combining site of the monoclonal Ig, whereas the latter may be tentatively assigned to a common genetic background.
A polyneuropathy occurs in about 5% ofpatients with Waldenstrom's macroglobulinemia (WM)' (4) . The pathogenesis of this severe complication is largely unknown. However, IgM deposits in nerves were demonstrated in some cases, (5-10) raising the intriguing possibility that the IgM mediates the nerve injury, possibly through an immunological interaction. We have therefore investigated the possibility that the monoclonal IgM from these patients may have crossidiotypic antigenic determinants and report in this paper that indeed a subgroup of patients with WM and neuropathy (interestingly, including two sisters) does in fact share cross-reactive idiotypes. Because it has previously been shown that coating erythrocytes with an IgM different from that used to prepare the anti-idiotypic serum offers a very sensitive system to reveal cross-idiotypic specificities among proteins with similar antibody activity (2, 13, 14) , further experiments were performed with IgM Gen as the coat and the anti-Vin as the agglutinating antiserum (Table II) (15, 16) . It must be noted that several idiotypic determinants are probably involved in our test system. Some antibodies reacted with antigenic determinants unique to the IgM Vin used for immunization, since the hemagglutinating system using the anti-Vin serum and erythrocytes coated with protein Vin could be inhibited only with the homologous IgM. The amount of protein needed to inhibit the cross-idiotypic system using anti Vin serum and erythrocyte coat Gen differed from one inhibitor to another. The presence of different crossidiotypic determinants was confirmed by gel precipitation because only a partial identity was observed between the three IgM proteins that gave a precipitin line with the absorbed anti-Vin antiserum. The other cross-idiotypic proteins (protein Can, Haa, and Cla) defined by hemagglutination inhibition did not precipitate with anti-Vin antiserum. By contrast, an additional IgM (Rab) from a patient with WM and neuropathy gave a reaction of partial identity with IgM Vin by precipitation, whereas it was negative by hemagglutination inhibition. It may therefore indicate the existence of another cross-idiotypic system different from the one described here.
METHODS
In two other systems, (IgM with anti-IgG or antierythrocyte antibody activity) the cross idiotypicity was clearly related to the combining site of the molecules because the monoclonal IgM no longer reacted with the anti-idiotypic serum when combined with their respective antigens (1, 2 It should also be stressed that antibodies only rarely mediate nerve injuries in experimental models (20) and that their role in human demyelinating diseases is still controversial (21) . Several mechanisms, apart from an antibody activity ofthe monoclonal IgM, may cause the neurologic symptoms observed in patients with WM: hyperviscosity, bleeding tendency, lymphoid infiltrates, and amyloidosis (4, 22) . In this context it should be stressed that in our experience, chemotherapy and/or plasmapheresis are successful in less than one-third of the patients with WM and neuropathy and it may well turn out that the effectiveness of the treatment is related to the mechanisms involved in nerve injury.
Those patients whose IgM possess idiotypic determinants such as those described in the present paper may well represent a subgroup in which plasmapheresis might be helpful. Our findings may therefore have therapeutic implications in the future.
Note added in proof. Since this manuscript was submitted, additional experiments using an idiotypic antiserum to the protein Rab showed the existence of a second cross-idiotypic system involving protein Rab and Vin as suggested in the discussion of this paper.
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